(Pictured left to right): Deborah Ley, PhD, Mahendra S. Rao, MD, PhD, Sir Gregory Winter, FRS, Igor Fisch, PhD, Nicolas Mermod, PhD, Marc Func, Ulrike Lemke, PhD, Thierry Schuepbach, PhD (Photo: Business Wire)

AAV pro­duc­er New­Bi­ologix emerges from stealth with $50M Se­ries A

An AAV-cen­tered biotech has come on­to the scene with $50 mil­lion in hand, look­ing to use an in-house plat­form to pro­duce a com­mon com­po­nent used in cell and gene ther­a­pies.

On Thurs­day, New­Bi­ologix an­nounced that it is work­ing on a DNA-based plat­form to ad­dress man­u­fac­tur­ing is­sues that come with de­vel­op­ing AAV vec­tors used in ad­vanced ther­a­pies. The Swiss com­pa­ny has come out of stealth with a $50 mil­lion Se­ries A.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.